Cellular uptake machinery and injured-tissue microenvironments

The term Cellular uptake machinery and injured-tissue microenvironments refers to a pharmacological strategy and physiological context rather than a single molecular target. It encompasses the biological processes of cellular internalization, such as endocytosis and vesicle transport, alongside the unique biochemical conditions found in damaged or diseased tissues, including acidic pH, hypoxia, and high protease activity (Zablotskii et al., 2018; Nie, 2010). In drug development, particularly within nanomedicine and regenerative medicine, these elements are exploited to design 'smart' delivery systems that remain stable in systemic circulation but release their therapeutic payload specifically at the site of injury or disease (JACS, 2023; ACS Nano, 2020). For instance, pH-responsive micelles or nanoparticles can be engineered to trigger drug release in the acidic environment of a tumor or an inflamed lesion, thereby increasing local efficacy while reducing systemic side effects (PMC, 2023). Additionally, targeting the cellular uptake machinery is essential for the delivery of large or charged molecules, such as mRNA or siRNA, which require specialized vehicles like lipid nanoparticles to bypass the cell membrane and reach their intracellular targets (Chemical Society Reviews, 2015).

Other names

Tissue microenvironment targetingStimuli-responsive drug deliveryEndocytic pathway exploitationSite-specific delivery to injured tissueMicroenvironment-responsive systems

Exploitation of physiological triggers such as acidic pH, hypoxia, or specific enzymes (e.g., MMPs) within injured tissues, combined with the utilization of cellular transport pathways (e.g., clathrin-mediated endocytosis or macropinocytosis) to achieve site-specific drug delivery and intracellular release.